Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

186.47
Delayed Data
As of Sep 18
 -1.00 / -0.53%
Today’s Change
133.64
Today|||52-Week Range
191.10
+27.54%
Year-to-Date
Novartis Announces Positive Data on Urticaria Drug Xolair
Sep 18 / Zacks.com - Paid Partner Content
Amgen Builds on a Breakout
Sep 12 / TheStreet.com - Paid Partner Content
Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle
Sep 16 / TheStreet.com - Paid Partner Content
Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA
Sep 12 / Zacks.com - Paid Partner Content
Top Research Reports for Philip Morris, Amgen & Union Pacific
Sep 15 / Zacks.com - Paid Partner Content
AbbVie's RA Candidate Meets Primary Endpoint in Phase III
Sep 12 / Zacks.com - Paid Partner Content
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval
Sep 15 / Zacks.com - Paid Partner Content
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
Sep 07 / Zacks.com - Paid Partner Content
FDA Approves First 'Biosimilar' for Cancer Treatment
Sep 14 / TheStreet.com - Paid Partner Content
AstraZeneca's COPD Candidate Duaklir Reports Positive Data
Sep 07 / Zacks.com - Paid Partner Content
Biosimilar 2017 Progress Report: Stocks in Focus
Sep 14 / Zacks.com - Paid Partner Content